EVAX Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -0.85%, SMA50 -23.16%, SMA200 -17.66%). The stock’s 14-day RSI is 41.37 (neutral), while the ATR of 0.31 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -73.25% below its high and over 170.83% above its low. Average 10-day trading volume of 27.87 thousand shares is below the 3-month average of 74.39 thousand, indicating normal recent market interest.

Evaxion Biotech A/S has 6.32 million shares outstanding. The public float is 177.29 million shares, elevated short interest at 2.47% of float. This equals 117.81 thousand shares. The short ratio is 1.03 days. Institutional investors hold 8.86% of the float. Insiders own 23.07%.

Evaxion Biotech A/S generated EPS of -$5.96 over the past year. Five-year average earnings growth is 22.22%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $10.00. The high target offers 396.89% upside. The low target suggests 210.56% downside. The mean target is $13.40. This offers 316.15% upside. Evaxion Biotech A/S earnings surprise history is a mixed track record. The quarter that ended August 14, 2025, missed forecasts by 52.0%. The prior quarter beat by -55.38%. Over the last six quarters, Apple has recorded several small beats. These include -105.45% in May 28, 2024.

Evaxion Biotech A/S last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.34. This means the shares are trading below this model’s fair value.

Evaxion Biotech A/S (NASDAQ:EVAX) closed at $3.22 USD, losing -$0.18 (-5.29%) from the previous close of $3.40. The stock is currently mid-range between its 52-week high and low $1.20 and $12.15. With a market capitalization of about $20.34 million, Evaxion Biotech A/S is classified as a micro-cap and shows lower-than-market volatility (beta ~0.29). Key stats such as the average daily volume over the past year has been around 74.03 thousand shares, volume is running light vs its 52-week average. Headquartered in Horsholm, None, Evaxion Biotech A/S operates in the Healthcare sector and the Biotechnology industry. Led by CEO Andreas Holm Mattsson, the company employs approximately 46 people and listed since February 05, 2021. Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections.

Evaxion Biotech A/S (NASDAQ:EVAX) shares are flat -1.89% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Evaxion Biotech A/S trading at a premium to the broader market with a P/E of -0.66. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.20, suggesting 278.88% upside. Our AI forecast model points to short-term weakness (-0.31% over two weeks), a medium-term fall (-4.35% over three months), and a longer-term gain (215.53% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Evaxion Biotech A/S stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.31%, with price expected at $3.21 by March 20, 2026, within a range of $3.00 to $3.42 3-Month Outlook: Projected fall of -4.35%, reaching $3.08 by June 04, 2026, with a range of $2.69 to $3.43. 1-Year Outlook: Projected gain of 215.53%, with price at $10.16 by March 05, 2027, within a range of $2.55 to $9.96.

Evaxion Biotech A/S trades at a P/E ratio of -0.66, slightly below the S&P 500 average, with a price-to-sales ratio of 2.67 and a price-to-book ratio of 0.22 suggesting the stock is closer to book value. The P/FCF stands at 0.0, also above market averages.